| 1 |
Members AF, Mancia G, Fagard R, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [J]. Eur Heart J, 2013, 31(10): 1925-1938.
|
| 2 |
Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe The Euro Heart Survey on diabetes and the heart [J]. Eur Heart J, 2004, 25(21): 1880-1890.
|
| 3 |
中国心脏调查组，胡大一，潘长玉. 中国住院冠心病患者糖代谢异常研究—中国心脏调查 [J]. 中华内分泌代谢杂志, 2006,(1):7-10.
|
| 4 |
Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [J]. Eur Heart J, 2014, 35(27): 1824-1824.
|
| 5 |
方丽娟，刘乃丰. 二甲双胍的心血管保护作用 [J]. 中国临床药理学与治疗学, 2011, 16(2): 232-236.
|
| 6 |
洪天配，母义明，纪立农, 等. 2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识 [J]. 中国糖尿病杂志, 2017, 25(6): 481-492.
|
| 7 |
Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects [J]. Diabetes Obes Metab, 2011, 13(7): 669-672.
|
| 8 |
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition [J]. Diabetologia, 2017, 60(2): 215-225.
|
| 9 |
DeFronzo RA, Morrow LA, Hompesch M, et al. Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes [J]. Diabetes Care, 2013, 36(10): 3169-3176.
|
| 10 |
Karin Rådholm, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program [J]. Circulation, 2018, 138(5): 458-468.
|
| 11 |
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes [J]. N Engl J Med, 2017, 377(7): 644-657.
|
| 12 |
Peene B, Benhalima K. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes [J]. Ther Adv Endocrinol Metab 2014, 5(5): 124-136.
|
| 13 |
Parveen R, Agarwal NB, Kaushal N, et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials [J]. Expert Opin Pharmacother, 2016, 17(1): 105-115.
|
| 14 |
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects [J]. Nat Rev Endocrinol, 2012, 8(8): 495-502.
|
| 15 |
Leiter, Lawrence A, Yoon, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study [J]. Diabetes Care, 2015, 38(3): 355-364.
|
| 16 |
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J]. Lancet, 2019, 393: 31-39.
|